News | September 09, 2025
Ichnos Glenmark Innovation receives upfront payment of $700 million from AbbVie
The payment is in accordance with the agreed contractual terms
The payment is in accordance with the agreed contractual terms
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The company has received approval from DCGI to begin patient enrolment and dosing in the country
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Subscribe To Our Newsletter & Stay Updated
